Unilateral prostate cancer cannot be accurately predicted in low-risk patients.

Link:
Autor/in:
Erscheinungsjahr:
2009
Medientyp:
Text
Beschreibung:
  • PURPOSE: Hemiablative therapy (HAT) is increasing in popularity for treatment of patients with low-risk prostate cancer (PCa). The validity of this therapeutic modality, which exclusively treats PCa within a single prostate lobe, rests on accurate staging. We tested the accuracy of unilaterally unremarkable biopsy findings in cases of low-risk PCa patients who are potential candidates for HAT. METHODS AND MATERIALS: The study population consisted of 243 men with clinical stage
  • PURPOSE: Hemiablative therapy (HAT) is increasing in popularity for treatment of patients with low-risk prostate cancer (PCa). The validity of this therapeutic modality, which exclusively treats PCa within a single prostate lobe, rests on accurate staging. We tested the accuracy of unilaterally unremarkable biopsy findings in cases of low-risk PCa patients who are potential candidates for HAT. METHODS AND MATERIALS: The study population consisted of 243 men with clinical stage
Lizenz:
  • info:eu-repo/semantics/restrictedAccess
Quellsystem:
Forschungsinformationssystem des UKE

Interne Metadaten
Quelldatensatz
oai:pure.atira.dk:publications/96cb2f9c-2d5b-457d-980c-c842df721606